The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: Results of a multicentre prospective study

Nephrology Dialysis Transplantation

Volumn 20, Issue 2, 2005, Pages 382-386

  Aucella, Filippo ^a   Margaglione, Maurizio ^a,b   Grandone, Elvira ^b   Vigilante, Mimmo ^a   Gatta, Giuseppe ^a   Forcella, Mauro ^c   Ktena, Maria ^c   De Min, Alva ^c   Salatino, Giovanna ^c   Procaccini, Deni Aldo ^c   Stallone, Carmine ^a   Gesualdo, Loreto ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c Department of Nephrology/Dialysis ^*  (Italy)

Author keywords

Cardiovascular disease; Dialysis; Genetics; Mortality; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTHESIS; ITALY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; UREMIA; VALIDATION PROCESS;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PERITONEAL DIALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL DIALYSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 14044261165     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh620     Document Type: Article

References (19)

1. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-457
2. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236
3. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996; 57: S11-S17
4. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141
5. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int Suppl 2001; 78: S234-S237
6. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
7. Födinger M, Mannhalter C, Wolf. G et al. Mutation (677°C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997: 52: 517-523
8. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60: 1106-1113
9. Haviv YS, Shpichinetsky V, Goldschmidt N, Atta IA, Ben-Yehuda A, Friedman G. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 2002; 92: 120-126
10. Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron 2002; 90: 43-50
11. Margaglione M, Colaizzo D, Cappucci G et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (mthfr) gene in offspring of patients with myocardial infarction. Thromb Haemostasis 1999; 82: 19-23
12. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 1999; 99: 2383-2388
13. Folsom AR, Nieto FJ, McGovern PG et al. Prospective study of coronary artery disease incidence in relation to fasting homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-210
14. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15: 442-453
15. Kalanthar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808
16. Frederiksen J, Juul K, Grande P et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004; 104: 3046-3051
17. Wrone EM, Hornberger JM, Zehnder JL et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426
18. Kimura H, Gejyo F, Suzuki S, Miyazaki R. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J Am Soc Nephrol 2000; 11: 885-893
19. Zychma MJ, Gumprecht J, Grzeszczak W, Zukowska-Szczechowska E. Methylenetetrahydrofolate reductase gene C677T polymorphism, plasma homocysteine and folate in end-stage renal disease dialysis and non-dialysis patients. Nephron 2002; 92: 235-239